Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2019

Open Access 01-10-2019 | Glioblastoma | PRECLINICAL STUDIES

The cellular effects of novel triazine nitrogen mustards in glioblastoma LBC3, LN-18 and LN-229 cell lines

Authors: Rafał Krętowski, Danuta Drozdowska, Beata Kolesińska, Zbigniew Kamiński, Justyna Frączyk, Marzanna Cechowska-Pasko

Published in: Investigational New Drugs | Issue 5/2019

Login to get access

Summary

1,3,5-triazine is an important heterocyclic skeleton for mono, two or three 2-chloroethylamine groups. The study presented here provides novel information on cellular effects of 1,3,5-triazine with mono, two or three 2-chloroethylamine groups in glioblastoma LBC3, LN-18 and LN-229 cell lines. In our study, the most cytotoxic effect was observed in 1,3,5-triazine with three 2-chloroethylamine groups (12f compound). It has been demonstrated that 12f induce time- and dose-dependent cytotoxicity in all investigated glioma cell lines. Apart from that in glioblastoma cells, treated with 12f compound, we noticed strong induction of apoptosis. In conclusion, this research provides novel information concerning cellular effects of apoptosis in LBC3, LN-18 and LN-229 cell lines. Moreover, we suggest that 12f compound may be a candidate for further evaluation as an effective chemotherapeutic agent for human glioblastoma cells.
Literature
1.
2.
Amberger-Murphy V (2009) Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 9:381–390CrossRefPubMed
3.
JJr P, Polivka J, Rohan V, Topolcan O, Ferda J (2012) New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res 32:2935–2946
4.
Burton EC, Lamborn KR, Forsyth P, Scott J, O’Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD (2002) Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8:180–187PubMed
5.
Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:2683–2710CrossRef
6.
Tomicic MT, Meise R, Aasland D, Berte N, Kitzinger R, Krämer OH, Kaina B, Christmann M (2015) Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNKc-Jun-mediated induction of the BH3-only protein BIM. Oncotarget 6:33755–33768CrossRefPubMedPubMedCentral
7.
Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585–2597PubMed
8.
Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
9.
Johnson DR, O’Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neuro-Oncol 107:359–364CrossRef
10.
Shahar T, Nossek E, Steinberg DM, Rozovski U, Blumenthal DT, Bokstein F, Sitt R, Freedman S, Corn BW, Kanner AA, Ram Z (2012) The impact of enrolment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci 19:1530–1534CrossRefPubMed
11.
Tong WP, Kirk MC, Ludlum DB (1982) Formation of the crosslink 1-[N3-deoxycytidyl), 2[N1-deoxyguanosinyl]-ethane in DNA treated with N,N′-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 42:3102–3105
12.
Ludlum DB (1997) The chloroethyl nitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Investig 15:588–598CrossRef
13.
Fischhaber PL, Gall AS, Duncan JA, Hopkins PB (1999) Direct demonstration in synthetic oligonucleotides that N,N′-bis(2-chloroethyl)-nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA. Cancer Res 59:4363–4384PubMed
14.
Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624–1636CrossRef
15.
Svechnikova I, Almqvist PM, Ekström TJ (2008) HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. Int J Oncol 32:821–827PubMed
16.
Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller W, Mehta MP, Gilbert MR (2008) Correlation of O6-methyl guanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199CrossRefPubMed
17.
Becker T, Gerke V, Kube E, Weber K (1992) S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 207:541–547CrossRefPubMed
18.
Sims JN, Graham B, Pacurari M, Leggett SS, Tchounwou PB, Ndebele K (2014) Di-ethylhexylphthalate (DEHP) modulates cell invasion, migration and anchorage independent growth through targeting S100P in LN-229 glioblastoma cells. Int J Environ Res Public Health 11:5006–5019CrossRefPubMedPubMedCentral
19.
Nielsen JS, McNagny KM (2009) The role of podocalyxin in health and disease. J Am Soc Nephrol 20:1669–1676CrossRefPubMed
20.
Wu H, Yang L, Liao D, Chen Y, Wang W, Fang J (2013) Podocalyxin regulates astrocytoma cell invasion and survival against temozolomide. Exp Ther Med 5:1025–1029CrossRefPubMedPubMedCentral
21.
Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O, Haglund C (2014) Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer 14:493–499CrossRefPubMedPubMedCentral
22.
Liu B, Liu Y, Jiang Y (2015) Podocalyxin promotes glioblastoma multiforme cell invasion and proliferation by inhibiting angiotensin-(1-7)/mas signalling. Oncology Rep 33:2583–2591CrossRef
23.
Povirk LF, Shuker DE (1994) DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 318:205–226CrossRefPubMed
24.
Colvin OM (1999) An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 5:55–60
25.
26.
Kolesińska B, Drozdowska D, Kamiński ZJ (2008) The new analogues of nitrogen mustard with one, two or three 2-chloroethyloamino fragments. Reactions with nucleophiles. Acta Polon Pharm 65:709–714
27.
Pomarnacka E, Bedarski P, Grunert R, Reszka P (2004) Synthesis and anticancer activity of novel 2-amino-4-(4-phenylpiperazino)-1,3,5-triazine derivatives. Acta Polon Pharm 61:461–467
28.
Raval JP, Rai AR, Patel NH, Patel HV, Patel PS (2009) Synthesis and in vitro antimicrobial activity of N’-(4-(aryloamino)-6-(pirydyn-2-yloamino)-1,3,5,-triazyn-2-yl)benzo-hydrazide. Int J Chem Tech Res 1:616–620
29.
Zacharie B, Abbott SD, Bienvenu JF, Cameron AD, Cloutier J, Duceppe JS, Ezzitouni A, Fortin D, Houde K, Lauzon C, Moreau N, Perron V, Wilb N, Asselin M, Doucet A, Fafard ME, Gaudreau D, Grouix B, Sarra-Bournet F, St-Amant N, Gagnon L, Penny CL (2010) 2,4,6-trisubstituted triazines as protein a mimetics for the treatment of autoimmune diseases. J Med Chem 53:1138–1145CrossRefPubMed
30.
Mandal S, Berube G, Asselin E, Mohammad I, Richardson VJ, Gupta A, Pramanik SK, Williams AL, Mandal SK (2007) A novel series of potent cytotoxic agents targeting G2/M phase of the cell cycle and demonstrating cell killing by apoptosis in human breast cancer cells. Bioorg Med Chem Lett 17:4955–4960CrossRefPubMed
31.
Kolesinska B, Barszcz K, Kaminski ZJ, Drozdowska D, Wietrzyk J, Switalska M (2012) Synthesis and cytotoxicity studies of bifunctional hybrids of nitrogen mustards with potential enzymes inhibitors based on melamine framework. J Enzym Inhib Med Chem 27:619–627CrossRef
32.
Frączyk J, Kolesińska B, Świątek M, Lipiński W, Drozdowska D, Kamiński ZJ (2016) Synthesis of arylo-1,3,5-triazines functionalized with alkylating 2-chloroethylamine fragments and studies of their cytotoxicity on the breast cancer MCF-7 cell line. Anti Cancer Agents Med Chem 16:1435–1444CrossRef
33.
Ventresca EM, Lecht S, Jakubowski P, Chiaverelli RA, Weaver M, Del Valle L, Ettinger K, Gincberg G, Priel A, Braiman A, Lazarovici P, Lelkes PI, Marcinkiewicz C (2015) Association of p75(NTR) and α9β integrin s modulates NGF-dependent cellular responses. Cell Signal 27:1225–1236CrossRefPubMedPubMedCentral
34.
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942
35.
Krętowski R, Kusaczuk M, Naumowicz M, Kotyńska J, Szynaka B, Cechowska-Pasko M (2017) The effects of silica nanoparticles on apoptosis and autophagy of glioblastoma cell lines. Nanomaterials (Basel) 21: 7(8) pii: E230. https://​doi.​org/​10.​3390/​nano7080230
36.
37.
Dao P, Lietha D, Etheve-Quelquejeu M, Garbay C, Chen H (2017) Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity. Bioorg Med Chem Lett 27:1727–1730CrossRefPubMed
38.
Dao P, Jarray R, Le Coq J, Lietha D, Loukaci A, Lepelletier Y, Hadj-Slimane R, Garbay C, Raynaud F, Chen H (2013) Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Bioorg Med Chem Lett 23:4552–4556CrossRefPubMed
39.
Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W (2008) Mechanisms of chemoresistance in malignant glioma. Clin Cancer Res 14:2900–2908CrossRefPubMedPubMedCentral
40.
Fu DJ, Song J, Hou YH, Zhao RH, Li JH, Mao RW, Yang JJ, Li P, Zi XL, Li ZH, Zhang QQ, Wang FY, Zhang SY, Zhang YB, Liu HM (2017) Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers. Eur J Med Chem 138:1076–1088CrossRefPubMedPubMedCentral
41.
Krętowski R, Borzym-Kluczyk M, Stypułkowska A, Brańska-Januszewska J, Ostrowska H, Cechowska-Pasko M (2016) Low glucose dependent decrease of apoptosis and induction of autophagy in breast cancer MCF-7 cells. Mol Cell Biochem 417:35–47CrossRefPubMedPubMedCentral
42.
43.
Krętowski R, Borzym-Kluczyk M, Cechowska-Pasko M (2014) Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231. Mol Cell Biochem 389:177–185CrossRefPubMedPubMedCentral
Metadata
Title
The cellular effects of novel triazine nitrogen mustards in glioblastoma LBC3, LN-18 and LN-229 cell lines
Authors
Rafał Krętowski
Danuta Drozdowska
Beata Kolesińska
Zbigniew Kamiński
Justyna Frączyk
Marzanna Cechowska-Pasko
Publication date
01-10-2019
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0712-8

Other articles of this Issue 5/2019

Investigational New Drugs 5/2019 Go to the issue

PRECLINICAL STUDIES

Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cells

PRECLINICAL STUDIES

Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo

PRECLINICAL STUDIES

Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib

Phase III Studies

The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States

PRECLINICAL STUDIES

The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling

PRECLINICAL STUDIES

Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits